The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients

nork Benoist, Guillemette E., van Oort, Inge M., Burger, David M., Mehra, Niven, van Erp, Nielka P.
Argitaratua izan da Cancer Chemother Pharmacol (2020)

Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy

nork Somford, Diederik M., van Oort, Inge M., Cosyns, Jean-Pierre, Witjes, J. Alfred, Kiemeney, Lambertus A. L. M., Tombal, Bertrand
Argitaratua 2011

PREDICT: model for prediction of survival in localized prostate cancer

nork Kerkmeijer, Linda G. W., Monninkhof, Evelyn M., van Oort, Inge M., van der Poel, Henk G., de Meerleer, Gert, van Vulpen, Marco
Argitaratua izan da World J Urol (2015)

Known susceptibility SNPs for sporadic prostate cancer show a similar association with “hereditary” prostate cancer

nork Cremers, Ruben G., Galesloot, Tessel E., Aben, Katja K., van Oort, Inge M., Vasen, Hans F., Vermeulen, Sita H., Kiemeney, Lambertus A.
Argitaratua izan da Prostate (2015)

The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited

nork Cremers, Ruben G., Aben, Katja K., van Oort, Inge M., Sedelaar, J.P. Michiel, Vasen, Hans F., Vermeulen, Sita H., Kiemeney, Lambertus A.
Argitaratua izan da Prostate (2016)

Drug–drug interaction potential in men treated with enzalutamide: Mind the gap

nork Benoist, Guillemette Emma, van Oort, Inge M., Smeenk, Stella, Javad, Adrian, Somford, Diederik M., Burger, David M., Mehra, Niven, van Erp, Nielka P.
Argitaratua izan da Br J Clin Pharmacol (2017)

Development and validation of a bioanalytical method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma: application to clinical managemen...

nork Benoist, Guillemette E, van der Meulen, Eric, van Oort, Inge M, Beumer, Jan Hendrik, Somford, Diederik M, Schalken, Jack A, Burger, David M, van Erp, Nielka P
Argitaratua izan da Ther Drug Monit (2018)

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients

nork Hendriks, Rianne J., Dijkstra, Siebren, Smit, Frank P., Vandersmissen, Johan, Van de Voorde, Hendrik, Mulders, Peter F. A., van Oort, Inge M., Van Criekinge, Wim, Schalken, Jack A.
Argitaratua izan da Prostate (2018)

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

nork Leyten, Gisele H. J. M., Wierenga, Elisabeth A., Michiel Sedelaar, J. P., van Oort, Inge M., Futterer, Jurgen J., Barentsz, Jelle O., Schalken, Jack A., Mulders, Peter F. A.
Argitaratua 2013

Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial

nork van Tol‐Geerdink, Julia J., Leer, Jan Willem H., Wijburg, Carl J., van Oort, Inge M., Vergunst, Henk, van Lin, Emile J., Witjes, J. Alfred, Stalmeier, Peep F. M.
Argitaratua izan da Health Expect (2015)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide

nork Benoist, Guillemette E., Hendriks, Rianne J., Mulders, Peter F. A., Gerritsen, Winald R., Somford, Diederik M., Schalken, Jack A., van Oort, Inge M., Burger, David M., van Erp, Nielka P.
Argitaratua izan da Clin Pharmacokinet (2016)

Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer

nork Smits, Minke, Ekici, Kamer, Pamidimarri Naga, Samhita, van Oort, Inge M., Sedelaar, Michiel J. P., Schalken, Jack A., Nagarajah, James, Scheenen, Tom W. J., Gerritsen, Winald R., Fütterer, Jurgen J., Mehra, Niven
Argitaratua izan da Cancers (Basel) (2020)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer

nork Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Mehra, Niven, Hins-de Bree, Simone M., Figdor, Carl G., Witjes, J. Alfred, Schreibelt, Gerty, de Vries, I. Jolanda M., Gerritsen, Winald R., Ottevanger, Petronella B.
Argitaratua izan da Front Oncol (2020)

Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative

nork Cuypers, Maarten, Al-Itejawi, Hoda H. M., van Uden-Kraan, Cornelia F., Stalmeier, Peep F. M., Lamers, Romy E. D., van Oort, Inge M., Somford, Diederik M., van Moorselaar, Reindert Jeroen A., Verdonck-de Leeuw, Irma M., van de Poll-Franse, Lonneke V., van Tol-Geerdink, Julia J., de Vries, Marieke
Argitaratua izan da J Cancer Educ (2019)

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer

nork Slootbeek, Peter H. J., Duizer, Marleen L., van der Doelen, Maarten J., Kloots, Iris S. H., Kuppen, Malou C. P., Westgeest, Hans M., Uyl‐de Groot, Carin A., Pamidimarri Naga, Samhita, Ligtenberg, Marjolijn J. L., van Oort, Inge M., Gerritsen, Winald R., Schalken, Jack A., Kroeze, Leonie I., Bloemendal, Haiko J., Mehra, Niven
Argitaratua izan da Int J Cancer (2020)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

nork Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., Gerritsen, Winald R.
Argitaratua izan da J Immunother Cancer (2019)

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

nork van Dessel, Lisanne F., van Riet, Job, Smits, Minke, Zhu, Yanyun, Hamberg, Paul, van der Heijden, Michiel S., Bergman, Andries M., van Oort, Inge M., de Wit, Ronald, Voest, Emile E., Steeghs, Neeltje, Yamaguchi, Takafumi N., Livingstone, Julie, Boutros, Paul C., Martens, John W. M., Sleijfer, Stefan, Cuppen, Edwin, Zwart, Wilbert, van de Werken, Harmen J. G., Mehra, Niven, Lolkema, Martijn P.
Argitaratua izan da Nat Commun (2019)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

nork Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., de Groot, Michel, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James
Argitaratua izan da BMC Cancer (2020)

Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility

nork Gudmundsson, Julius, Sulem, Patrick, Gudbjartsson, Daniel F., Blondal, Thorarinn, Gylfason, Arnaldur, Agnarsson, Bjarni A., Benediktsdottir, Kristrun R., Magnusdottir, Droplaug N., Orlygsdottir, Gudbjorg, Jakobsdottir, Margret, Stacey, Simon N., Sigurdsson, Asgeir, Wahlfors, Tiina, Tammela, Teuvo, Breyer, Joan P., McReynolds, Kate M., Bradley, Kevin M., Saez, Berta, Godino, Javier, Navarrete, Sebastian, Fuertes, Fernando, Murillo, Laura, Polo, Eduardo, Aben, Katja K., van Oort, Inge M., Suarez, Brian K., Helfand, Brian T., Kan, Donghui, Zanon, Carlo, Frigge, Michael L., Kristjansson, Kristleifur, Gulcher, Jeffrey R., Einarsson, Gudmundur V., Jonsson, Eirikur, Catalona, William J., Mayordomo, Jose I., Kiemeney, Lambertus A., Smith, Jeffrey R., Schleutker, Johanna, Barkardottir, Rosa B., Kong, Augustine, Thorsteinsdottir, Unnur, Rafnar, Thorunn, Stefansson, Kari
Argitaratua 2009

A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer

nork Gudmundsson, Julius, Sulem, Patrick, Gudbjartsson, Daniel F., Masson, Gisli, Agnarsson, Bjarni A., Benediktsdottir, Kristrun R., Sigurdsson, Asgeir, Magnusson, Olafur Th., Gudjonsson, Sigurjon A., Magnusdottir, Droplaug N., Johannsdottir, Hrefna, Helgadottir, Hafdis Th., Stacey, Simon N., Jonasdottir, Adalbjorg, Olafsdottir, Stefania B., Thorleifsson, Gudmar, Jonasson, Jon G., Tryggvadottir, Laufey, Navarrete, Sebastian, Fuertes, Fernando, Helfand, Brian T., Hu, Qiaoyan, Csiki, Irma E., Mates, Ioan N., Jinga, Viorel, Aben, Katja K. H., van Oort, Inge M., Vermeulen, Sita H., Donovan, Jenny L., Hamdy, Freddy C., Ng, Chi-Fai, Chiu, Peter K.F., Lau, Kin-Mang, Ng, Maggie C.Y., Gulcher, Jeffrey R., Kong, Augustine, Catalona, William J., Mayordomo, Jose I., Einarsson, Gudmundur V., Barkardottir, Rosa B., Jonsson, Eirikur, Mates, Dana, Neal, David E., Kiemeney, Lambertus A., Thorsteinsdottir, Unnur, Rafnar, Thorunn, Stefansson, Kari
Argitaratua 2012